News

Amplexa continues investing in new technologies with the arrival of NGS platforms.

 

Amplexa pursues its investments in cutting edge technology with achievement of NGS platforms. With the capability to perform massive parallel sequencing using PGM (Personal Genome Machine) the construction of panels for cancer, epilepsy or population specific gene variant panels are now at hand. Acquisition of Ion Torrent technology further allows whole genome CNV detection, RNA seq, ChipSeq and numerous other applications.